DBV TECHNOLOGIES News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

11.04.16	DBV Technologies Announces Publication of Experimental Data on Targeted Regulatory T Cell Induction during Epicutaneous Immunotherapy (GlobeNewswire)
07.04.16	DBV Technologies Reports Full Year 2015 Financial Results (GlobeNewswire)
06.03.16	DBV Technologies: Additional Phase IIb Trial Results with Viaskin Peanut Presented at the 2016 AAAAI Meeting Continue to Support Treatment Safety, Efficacy and Compliance (GlobeNewswire)
04.03.16	DBV Technologies Announces Presentation from NIAID-sponsored CoFAR6 Phase II Trial Reaffirming Viaskin® Peanut Safety and Efficacy (GlobeNewswire)
01.03.16	DBV Technologies to Attend Upcoming Investor Conferences and Events (GlobeNewswire)
25.02.16	DBV Technologies Announces Publication of Phase Ib Trial Results in the Journal of Allergy and Clinical Immunology (JACI) Supporting Safety and Tolerability of Viaskin® Peanut (GlobeNewswire)
15.02.16	DBV Technologies Reports December 31, 2015, Cash Position (GlobeNewswire)
10.02.16	DBV Technologies to Present New Data at the 2016 AAAAI Annual Meeting (GlobeNewswire)
08.02.16	DBV Technologies to Present at the LEERINK Partners 5th Annual Global Healthcare Conference (GlobeNewswire)
26.01.16	DBV Technologies Proudly Welcomes Edward Jordan as Senior Vice President Commercial Operations North America (GlobeNewswire)
08.01.16	DBV Technologies Announces 2016 Financial Calendar (GlobeNewswire)
10.12.15	DBV Technologies: First Experimental Results for the Treatment of Colitis with Viaskin® will be presented at the Crohn's & Colitis Foundation of America's 2015 Advances in IBD Conference (AIBD) (GlobeNewswire)
07.12.15	DBV Technologies Announces Initiation of Phase III Study of Viaskin® Peanut for the Treatment of Peanut Allergic Children (GlobeNewswire)
18.11.15	DBV Technologies to Present Preclinical Data on its Viaskin® Technology for RSV Vaccination at the 2015 RSV Vaccines for the World Meeting (GlobeNewswire)
12.11.15	DBV Technologies Announces Enrollment of First Patient in Phase IIA Study in Pediatric Eosinophilic Esophagitis (GlobeNewswire)
03.11.15	DBV Technologies Reports Interim Financial Results for the third quarter of 2015 (GlobeNewswire)
01.09.15	DBV Technologies : DBV Technologies' Extraordinary General Assembly on September 21, 2015 (GlobeNewswire)
08.07.15	DBV Technologies : IND Acceptance from FDA for a proof-of-concept trial using Viaskin® Milk in Milk-Induced Eosinophilic Esophagitis in Children (GlobeNewswire)
02.07.15	DBV Technologies :Monthly information regarding the total number of voting rights and total number of shares of the Company (GlobeNewswire)
30.06.15	DBV Technologies Announces Completion of Part A of the MILES Study Evaluating the Safety of Viaskin® Milk in Pediatric Cow's Milk Allergy (GlobeNewswire)
26.06.15	DBV Technologies Proudly Welcomes Dr. Hugh Sampson as Chief Scientific Officer (GlobeNewswire)
23.06.15	DBV Technologies' June 23, 2015 Combined Shareholders' Meeting (GlobeNewswire)
04.06.15	DBV Technologies Announces EMA Paediatric Committee (PDCO) positive opinion on the Paediatric Investigation Plan for Viaskin® Peanut for the Treatment of Peanut Allergic Children (GlobeNewswire)
28.10.14	Citi Appointed Depositary Bank for DBV Technologies’ ADR Programme (Businesswire)
27.09.13	Company Profile for DBV Technologies (Businesswire)
15.01.13	DBV Technologies and INRA Receive Funding to Develop Pediatric Bronchiolitis (‘RSV’) Vaccine: RSV-NanoViaSkin (Businesswire)
02.01.13	DBV Technologies : Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company (Businesswire)
02.01.13	DBV Technologies : Half Year Update on the DBV Technologies Liquidity Agreement (Businesswire)
18.12.12	DBV Technologies’ 2013 Financial calendar (Businesswire)
05.12.12	DBV Technologies : Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company (Businesswire)
14.11.12	DBV Technologies launches its third Viaskin® program, a first for the treatment of House Dust Mites (HDM) allergy in young children (Businesswire)
06.11.12	DBV Technologies : Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company (Businesswire)
16.10.12	DBV Technologies and Centre d'Immunologie de Marseille-Luminy (CIML) enter in a Collaboration Agreement (Businesswire)
15.10.12	DBV Technologies: First nine months topline and clinical and business highlights (Businesswire)
02.10.12	DBV Technologies : Monthly information regarding the total number of voting rights and total number of shares of the Company (Businesswire)
02.10.12	DBV Technologies: Monthly information regarding the total number of voting rights and total number of shares of the Company (Businesswire)
02.08.12	DBV Technologies initiates VIPES phase IIb clinical study, the first global trial ever in desensitization of peanut-allergic children and adults (Businesswire)
26.07.12	Half year update on the DBV Technologies liquidity agreement contracted with NATIXIS (Businesswire)
26.07.12	Half Year 2012 results and R&D highlights: DBV Technologies on track (Businesswire)
19.07.12	DBV Technologies Welcomes Mr. Stef Koppelman as Its New General Scientific Advisor (Businesswire)
18.06.12	DBV Technologies: Positive Interim Clinical Data in Peanut Allergic Children Treated with VIASKIN PEANUT (Businesswire)
06.06.12	DBV Technologies’ June 6th 2012 Ordinary Meeting of Shareholders (Businesswire)
31.05.12	Professor Hugh Sampson Joins Scientific Advisory Board of DBV Technologies (Businesswire)
15.05.12	DBV Technologies: First Quarter 2012 Topline, Scientific Activity and Upcoming Clinical Data (Businesswire)
10.05.12	DBV Technologies Welcomes Charles Ruban as Chief Development Officer (Businesswire)
26.04.12	DBV Technologies increases the size of its initial public offering to €40.6 million through the partial exercise of the overallotment option (Businesswire)
26.04.12	DBV Technologies: Implementation of a liquidity agreement with Natixis (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’263.50	2.89 %	K V
Sonova Hldg	312.10	2.66 %	K V
Novartis	93.68	2.32 %	K V
Geberit	526.80	1.97 %	K V
Roche Hldg G	254.30	1.27 %	K V
Kuehne+Nagel Int	209.50	0.72 %	K V
UBS Group	28.30	0.57 %	K V
Givaudan	3’933.00	0.36 %	K V
Nestle	76.00	0.05 %	K V
Lonza Grp	521.40	-0.04 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu DBV TECHNOLOGIES

Aktien Top/Flop

Meistgelesene Nachrichten